Hepatitis B virus (HBV) is a significant global pathogen, infecting more than 240 million
people worldwide. While treatment for HBV has improved, HBV patients often require …

As obligate intracellular parasites, viruses need a host cell to provide a milieu favorable to
viral replication. Consequently, viruses often adopt mechanisms to subvert host cellular …

Introducing novel strategies, concepts, and technologies that speed up drug discovery and
the drug development cycle is of great importance both in the highly competitive …

Hepatitis B virus is one of the smallest human pathogens, encoded by a 3,200-bp genome
with only four open reading frames. Yet the virus shows a remarkable diversity in structural …

Hepatitis B virus (HBV) infection affects approximately 300 million people worldwide.
Although antiviral therapies have improved the long-term outcomes, patients often require …

Highlights•Five nucleoside inhibitors of HBV polymerase have been approved for clinical
use.•HBV polymerase protein priming activity is inhibited by purine analogs.•Entecavir and …

Hallmarks of the hepadnavirus replication cycle are the formation of covalently closed
circular DNA (cccDNA) and the reverse transcription of a pregenomic RNA (pgRNA) in core …

Hepatitis B virus infection affects over 250 million chronic carriers, causing more than
800,000 deaths annually, although a safe and effective vaccine is available. Currently used …

Reverse transcriptases (RTs) play a major role in the replication of Retroviridae,
Metaviridae, Pseudoviridae, Hepadnaviridae and Caulimoviridae. RTs are enzymes that are …

Background & Aims Covalently closed circular DNA (cccDNA) is the episomal form of the
HBV genome that stably resides in the nucleus of infected hepatocytes. cccDNA is the …